NYSE American (AMEX)
15-minute delay
NANOVIRICIDES, INC. COVERAGE
Latest NanoViricides, Inc. news
accessnewswire.com · Sep 15, 2026
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in
DR Congo with 48% Crude Fatality Rate, Says NanoViricides
Read article →
accessnewswire.com · Sep 8, 2026
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
Read article →
accessnewswire.com · Aug 31, 2026
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
Read article →
defenseworld.net · Aug 21, 2026
NanoViricides (NYSE:NNVC) Trading Down 2.2% – Time to Sell?
Read article →
accessnewswire.com · Aug 18, 2026
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
Read article →
accessnewswire.com · Aug 10, 2026
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
Read article →
KEY DATA POINTS
Financial snapshot
Revenue, profitability, balance-sheet, cash-flow, and valuation
trends for NanoViricides, Inc..
AMEX MARKET COMPARABLES
Ten established AMEX listings presented for broader market context.
AMEX reference
15-minute delay
TradingView renders the market-data table. Securities.io supplies only
the editorial peer selection, comparison labels, and destination links.
COMPANY DETAILS
About NanoViricides, Inc.
Business description, sector, industry, leadership, headquarters,
and workforce information.
SECURITIES.IO RESEARCH
Continue your research
AMEX market data on this page is
labeled as 15 minutes delayed. Prices,
charts, financials, company information, and the peer comparison are
displayed by TradingView; Securities.io does not extract those values.
This information is educational and is not investment advice.